Vor Biopharma Inc
VOR0.151USD
-0.008-5.44%
收盘 05/09, 16:00（美东）报价延迟15分钟
18.88M总市值
亏损市盈率 TTM
关于 Vor Biopharma Inc 公司
Vor Biopharma Inc. 是一家临床阶段的细胞和基因组工程治疗公司。该公司致力于将新型患者工程方法与靶向疗法相结合，为患有血液系统恶性肿瘤的患者提供解决方案。其专有平台利用造血干细胞 (HSC) 生物学、基因组工程和靶向疗法开发方面的专业知识，对 HSC 进行基因改造，以去除癌细胞表达的表面靶标。该公司的主要工程造血干细胞 (eHSC) 候选产品包括 tremtelectogene empogeditemcel (trem-cel)，用于治疗急性髓系白血病 (AML) 和其他血癌。它旨在取代患有急性髓系白血病 (AML) 和其他血癌的患者的移植标准护理。其 VBP101 是一项 I/II 期多中心、开放标签、首次在 AML 患者身上进行的 trem-cel 研究。
公司简介
公司代码VOR
公司名称Vor Biopharma Inc
上市日期Feb 05, 2021
成立日期2015
CEODr. Robert Ang, M.D.
员工数量159
证券类型Ordinary Share
年结日Feb 05
公司地址100 Cambridgepark Drive
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02140
电话16176556580
网址https://www.vorbio.com/
公司代码VOR
上市日期Feb 05, 2021
成立日期2015
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Tirtha Chakraborty, Ph.D.
Dr. Tirtha Chakraborty, Ph.D.
Chief Scientific Officer and Head of Technical Operations
Chief Scientific Officer and Head of Technical Operations
80.28K
-3.40%
Mr. Matthew R. Patterson
Mr. Matthew R. Patterson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
41.20K
+3.36%
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
Independent Director
Independent Director
29.43K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Dr. Han Choi, M.D.
Dr. Han Choi, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Robert Ang, M.D.
Dr. Robert Ang, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Tirtha Chakraborty, Ph.D.
Dr. Tirtha Chakraborty, Ph.D.
Chief Scientific Officer and Head of Technical Operations
Chief Scientific Officer and Head of Technical Operations
80.28K
-3.40%
Mr. Matthew R. Patterson
Mr. Matthew R. Patterson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
41.20K
+3.36%
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
Independent Director
Independent Director
29.43K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 4月18日 周五
更新时间: 4月18日 周五
持股股东
股东类型
持股股东
股东统计
占比
RA Capital Management, LP
31.75%
Reprogrammed Interchange LLC
31.22%
5AM Ventures
5.10%
Fidelity Management & Research Company LLC
5.07%
The Vanguard Group, Inc.
1.56%
Other
25.31%
持股股东
股东统计
占比
RA Capital Management, LP
31.75%
Reprogrammed Interchange LLC
31.22%
5AM Ventures
5.10%
Fidelity Management & Research Company LLC
5.07%
The Vanguard Group, Inc.
1.56%
Other
25.31%
股东类型
股东统计
占比
Hedge Fund
33.29%
Corporation
31.22%
Investment Advisor
7.09%
Venture Capital
6.26%
Investment Advisor/Hedge Fund
2.57%
Individual Investor
0.70%
Research Firm
0.21%
Bank and Trust
0.01%
Other
18.65%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
171
101.61M
81.40%
+39.01M
2024Q4
172
101.57M
81.78%
+39.14M
2024Q3
175
49.60M
72.03%
-12.93M
2024Q2
174
56.25M
82.04%
-8.25M
2024Q1
168
60.63M
88.57%
-4.75M
2023Q4
163
60.90M
89.54%
-3.77M
2023Q3
164
61.10M
90.20%
-4.10M
2023Q2
166
61.68M
92.10%
-1.24M
2023Q1
168
61.85M
93.27%
-1.28M
2022Q4
162
61.21M
94.78%
+26.97M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
39.65M
31.75%
+16.90M
+74.28%
Dec 31, 2024
Reprogrammed Interchange LLC
38.97M
31.22%
+38.97M
--
Dec 30, 2024
5AM Ventures
6.36M
5.1%
--
--
Dec 31, 2024
Fidelity Management & Research Company LLC
6.33M
5.07%
-649.38K
-9.30%
Dec 31, 2024
The Vanguard Group, Inc.
1.94M
1.56%
-11.46K
-0.59%
Dec 31, 2024
Johnson & Johnson Innovation-JJDC, Inc.
1.07M
0.86%
--
--
Dec 31, 2024
Lynx1 Capital Advisors LLC
637.22K
0.51%
+637.22K
--
Dec 31, 2024
Sarissa Capital Management, L.P.
618.00K
0.49%
--
--
Dec 31, 2024
Ang (Robert M.D.)
646.69K
0.52%
+131.47K
+25.52%
Feb 06, 2025
Renaissance Technologies LLC
529.50K
0.42%
-226.51K
-29.96%
Dec 31, 2024
查看更多
持股ETF
更新时间: 5月6日 周二
更新时间: 5月6日 周二
机构名称
占比
Range Cancer Immunotherapy ETF
1.25%
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
Range Cancer Immunotherapy ETF
占比1.25%
iShares Micro-Cap ETF
占比0.01%
ProShares UltraPro Russell2000
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
iShares Russell 2000 ETF
占比0%
Global X Russell 2000 ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
Proshares Ultra Russell 2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据